IRG1-Itaconic Acid Axis Restrains TBK1-Driven Type I IFN Res
2026-05-25
Chai et al. (2025) elucidate how the IRG1-generated metabolite itaconic acid directly alkylates TBK1, disrupting its activation and providing negative feedback on type I interferon signaling. This mechanistic insight advances understanding of metabolic-immunological crosstalk and supports development of selective pathway inhibitors for diseases linked to hyperinflammation.
Adipose-Neural Axis in Epicardial Fat-Linked Cardiac Arrhyth
2026-05-24
Fan et al. (2024) present direct evidence that the adipose-neural axis, mediated through leptin and neuropeptide Y signaling, plays a pivotal role in epicardial adipose tissue (EAT)-related cardiac arrhythmias. Their coculture model reveals mechanistic pathways and therapeutic targets relevant to arrhythmogenesis in atrial fibrillation.
Mitochondrial-Linked Apoptosis and Muscle Atrophy in Ovarian
2026-05-23
This study interrogates whether mitochondrial ROS-triggered apoptosis or necroptosis drive skeletal muscle atrophy during ovarian cancer progression in mice. Using the mitochondrial-targeted antioxidant SkQ1, the authors reveal that inhibiting mitochondrial apoptosis does not prevent muscle loss, challenging assumptions about cell death pathways in cancer cachexia.
RESTRICT-seq Unveils KAT6A-Dependent Epigenetic Resistance i
2026-05-22
The reference study introduces RESTRICT-seq, a time-gated CRISPR screening method that uncovers new epigenetic dependencies underlying resistance in squamous cell carcinoma (SCC). By functionally dissecting KAT6A’s role in oncogene-induced senescence and therapeutic response, the work provides actionable insights for precision epigenetic research.
Tubastatin A Mitigates Myocardial Damage Post-Cardiac Arrest
2026-05-22
The referenced study demonstrates that Tubastatin A, a highly selective HDAC6 inhibitor, significantly reduces post-resuscitation myocardial injury in a porcine cardiac arrest model. This cardioprotective effect is linked to suppression of GSDME-mediated pyroptosis and MLKL-mediated necroptosis, offering new mechanistic insights for translational cardiac research.
Norovirus Hijacks NINJ1 for Selective Viral Protein Secretio
2026-05-21
This study reveals that murine norovirus co-opts the host membrane protein NINJ1 to selectively secrete the viral NS1 protein, leveraging an unconventional pathway involving caspase-3 cleavage. These findings provide new insight into how viruses manipulate regulated cell death and membrane rupture for immune evasion.
Patient-Derived Gastric Cancer Assembloids Reveal Tumor-Stro
2026-05-21
This study establishes a novel gastric cancer assembloid model integrating matched tumor organoids and stromal subpopulations, capturing tumor microenvironment complexity. The model enables nuanced analysis of gene expression and drug responses, advancing preclinical and personalized cancer research.
Adipose-Neural Axis Drives Arrhythmia via Leptin–NPY/Y1R Sig
2026-05-20
Fan et al. (2024) demonstrate that epicardial adipose tissue (EAT) interacts with cardiac sympathetic neurons to trigger arrhythmia through a leptin–NPY/Y1R pathway, using a novel stem cell-based coculture model. Their findings identify actionable molecular targets for arrhythmia intervention and offer a foundational platform for translational NPY/NPFF system research.
CDK9 Inhibitor (A3294): Technical Protocols and Workflow Set
2026-05-20
The CDK9 inhibitor (A3294) enables selective, non-cytotoxic inhibition of cyclin dependent kinase 9, making it suitable for studies on transcription elongation and HIV-1 propagation inhibition. It should not be used in protocols requiring pan-CDK inhibition or long-term storage of working solutions. Proper solubility and handling are essential for reproducible results.
HotStart 2X Green qPCR Master Mix: Precision for Translation
2026-05-19
Explore how HotStart 2X Green qPCR Master Mix advances real-time PCR gene expression analysis and RNA-seq validation with superior specificity. This article connects molecular assay optimization to translational research, offering a unique bridge for biotechnologists.
Dabigatran: A Paradigm Shift in Thromboembolic Disease Thera
2026-05-19
This review analyzes the pivotal role of dabigatran—a direct thrombin inhibitor—in the prevention and treatment of thromboembolic disorders. The study highlights clinical advantages over vitamin K antagonists, such as improved safety, predictable pharmacokinetics, and reduced monitoring needs, with implications for optimizing anticoagulation therapy in cardiovascular research and practice.
Efficient Synthesis of Deuterium-Labeled Degarelix Acetate:
2026-05-18
This study details a streamlined, high-yield method for synthesizing deuterium-labeled degarelix acetate, a valuable internal standard for pharmacokinetic and metabolism research of androgen-related diseases. The work's methodological innovations support enhanced analytical precision in clinical studies, enabling more robust evaluation of drug metabolism and distribution.
Viral RIPK3 Degradation Modulates Necroptosis and Inflammati
2026-05-18
Liu et al. identify a class of orthopoxvirus proteins that promote proteasomal degradation of the necroptosis adaptor RIPK3, thereby suppressing necroptosis and influencing virus-induced inflammation and pathogenesis. These findings elucidate a viral immune evasion strategy and advance our understanding of host-pathogen interactions, with implications for antiviral research and necroptosis-targeted assays.
Caffeine in Translational Research: Mechanisms and Momentum
2026-05-17
Explore how Caffeine (1,3,7-trimethylpurine-2,6-dione) is redefining the landscape of cancer and metabolic research—from the molecular antagonism of adenosine receptors to strategic assay design for translational outcomes. This thought-leadership article synthesizes mechanistic insights, experimental evidence, and the competitive research ecosystem. Drawing from recent advances in enzyme-targeted therapies and rigorously validated protocols, it offers actionable guidance for researchers seeking to bridge laboratory findings with clinical impact.
Iptacopan (LNP023): Potent Oral Factor B Inhibitor for Compl
2026-05-16
Iptacopan (LNP023) is a highly selective, orally bioavailable inhibitor of complement factor B. It achieves submicromolar blockade of alternative pathway activity and has demonstrated efficacy in clinical and animal models of complement-mediated disease. Peer-reviewed data and product benchmarks validate its use in both mechanistic and translational research.
465 records 18/31 page Previous Next First page 上5页 1617181920 下5页 Last page